Finance

Lists
GIS:FRA
Gilead Sciences, Inc
โ‚ฌ132,92
+0,05%
(+0,060) 1D
1 Okt., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
โ‚ฌ131,24
High
โ‚ฌ132,92
Low
โ‚ฌ131,24
Mkt. cap
182,89ย mjd
Avg. vol.
439,00
Volume
30,00
52-wk high
โ‚ฌ134,58
52-wk low
โ‚ฌ93,70
No. of employees
17ย k
Open
โ‚ฌ131,24
High
โ‚ฌ132,92
Low
โ‚ฌ131,24
Mkt. cap
182,89ย mjd
Avg. vol.
439,00
Volume
30,00
52-wk high
โ‚ฌ134,58
52-wk low
โ‚ฌ93,70
No. of employees
17ย k
News stories
From web sources and news partners
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17ย k
Founded22 Jun. 1987
HeadquartersFoster City, Kaliforniรซ, Verenigde State van Amerika
Sector-
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
7,77ย mjd
7,92ย mjd
6,96ย mjd
7,80ย mjd
Cost of goods sold
1,57ย mjd
1,62ย mjd
1,44ย mjd
1,58ย mjd
Cost of revenue
1,57ย mjd
1,62ย mjd
1,44ย mjd
1,58ย mjd
Research and development expenses
1,33ย mjd
1,57ย mjd
1,36ย mjd
1,69ย mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,35ย mjd
1,78ย mjd
1,43ย mjd
1,91ย mjd
Operating expense
2,69ย mjd
3,34ย mjd
2,78ย mjd
3,60ย mjd
Total operating expenses
4,26ย mjd
4,96ย mjd
4,23ย mjd
5,18ย mjd
Operating income
3,51ย mjd
2,96ย mjd
2,73ย mjd
2,63ย mjd
Other non operating income
-23,00ย m
51,00ย m
-8,00ย m
-
EBT including unusual items
3,64ย mjd
2,08ย mjd
2,58ย mjd
-10,25ย mjd
EBT excluding unusual items
3,34ย mjd
2,80ย mjd
2,59ย mjd
2,42ย mjd
Income tax expense
589,00ย m
-105,00ย m
559,00ย m
242,00ย m
Effective tax rate
16,18%
-5,05%
21,67%
-2,36%
Other operating expenses
-
-
-
-
Net income
3,05ย mjd
2,18ย mjd
2,02ย mjd
-10,50ย mjd
Net profit margin
39,28%
27,55%
29,04%
-134,51%
Earnings per share
2,47
1,86
2,03
-6,75
Interest and investment income
88,00ย m
95,00ย m
95,00ย m
45,00ย m
Interest expense
-256,00ย m
-255,00ย m
-240,00ย m
-247,00ย m
Net interest expenses
-168,00ย m
-160,00ย m
-145,00ย m
-202,00ย m
Depreciation and amortization charges
-
-
-
-
EBITDA
4,20ย mjd
3,65ย mjd
3,42ย mjd
3,33ย mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme